Phase transformation considerations during process development and manufacture of solid oral dosage forms
about
Polymorph Impact on the Bioavailability and Stability of Poorly Soluble DrugsAssessment of Efficacy and Quality of Two Albendazole Brands Commonly Used against Soil-Transmitted Helminth Infections in School Children in Jimma Town, EthiopiaIn situ 3D topographic and shape analysis by synchrotron radiation X-ray microtomography for crystal form identification in polymorphic mixturesRapid insight into heating-induced phase transformations in the solid state of the calcium salt of atorvastatin using multivariate data analysis.Structural Properties, Order-Disorder Phenomena, and Phase Stability of Orotic Acid Crystal Forms.A kinetic study of the polymorphic transformation of nimodipine and indomethacin during high shear granulation.Navigating the Waters of Unconventional Crystalline Hydrates.Advances in solid dosage form manufacturing technology.Excipient selection can significantly affect solid-state phase transformation in formulation during wet granulationAnalysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy.Spray granulation for drug formulation.An overview of famotidine polymorphs: solid-state characteristics, thermodynamics, polymorphic transformation and quality control.The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.Intestinal solubility and absorption of poorly water soluble compounds: predictions, challenges and solutions.Moisture Sorption-desorption Characteristics and the Corresponding Thermodynamic Properties of Carvedilol PhosphateRational excipient selection for co-amorphous formulations.Stable amorphous binary systems of glipizide and atorvastatin powders with enhanced dissolution profiles: formulation and characterization.Computational and Experimental Characterization of Five Crystal Forms of Thymine: Packing Polymorphism, Polytypism/Disorder and Stoichiometric 0.8-HydrateQuantitative measurement of indomethacin crystallinity in indomethacin-silica gel binary system using differential scanning calorimetry and X-ray powder diffractometry.Use of drifts and PLS for the determination of polymorphs of piroxicam alone and in combination with pharmaceutical excipients: a technical note.Structural basis for the transformation pathways of the sodium naproxen anhydrate-hydrate system.Insights into hydrate formation and stability of morphinanes from a combination of experimental and computational approaches.Effect of sample preparation method on quantification of polymorphs using PXRD.Exploring the solid-form landscape of pharmaceutical hydrates: transformation pathways of the sodium naproxen anhydrate-hydrate system.Eutectics as improved pharmaceutical materials: design, properties and characterization.Effect of particle size on energy dissipation in viscoelastic granular collisions.Real-time assessment of critical quality attributes of a continuous granulation process.Monitoring real time polymorphic transformation of sulfanilamide by diffuse reflectance visible spectroscopy.Heating system of pellet samples integrated with terahertz spectrometer.Stability of pharmaceutical salts in solid oral dosage forms.Influences of Crystal Anisotropy in Pharmaceutical Process Development.Controlled production of the elusive metastable form II of acetaminophen (paracetamol): a fully scalable templating approach in a cooling environment.Polymorphic transformation of artemisinin by high temperature extrusionNanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability
P2860
Q26779030-05FDE4C2-F5FB-415E-9570-FB79EFA744D3Q28548540-D0509887-A60E-499E-B662-4F02EEA83F79Q28834486-FC552E30-F789-4E77-8FB4-2B43A5F78174Q30576885-FF5E28C5-0961-4AEA-8984-A6B4A9DBB687Q31035808-C0140C3B-A076-4293-9F61-60F0E6D01FAFQ35100389-4A9A730C-B6BF-45B0-9632-06A9569C64D3Q35663589-4FDDD79F-AFD3-44EF-A548-2D483A949F5EQ36940354-97668B78-2451-45B9-9E5C-2F9799DC905DQ37360836-D890F15A-264D-4C41-BFD7-0F5286E9742BQ37585656-1713688C-7824-4234-9FF0-AC16365B6057Q37957960-F71C7825-B440-403F-9761-B1980E917281Q38191851-A343E585-159D-40F8-810F-9AA5048D0D86Q38239948-DA79D31D-D75B-4BD9-92E9-7B86E164A7E0Q38575611-9B3A3EC2-3DB2-42C0-B05C-6305A90151C6Q38741902-6FF0AB37-6C21-4F98-8076-4AEA3D493BD2Q38856865-A5B54D01-9AAD-4EA8-9520-94A96587EE97Q40167348-818D5AD8-632A-479B-92C4-38ED61CF80CBQ41031460-83F821B7-2536-4BE6-83F8-42E240814A45Q41840018-3F6FEFB4-914E-45C2-BC76-7029257F150CQ42374416-6B794F05-6754-432B-85C5-5B13F4FA9B00Q42914903-25655E08-86FB-46BB-9ACC-827728C031DAQ43121947-612AD863-AD6F-4D2B-8367-C1AF3E42C879Q43258279-D5CE7894-FB00-4119-8A98-BD1B6D33FF81Q43759362-CD4160E7-F71B-4260-97D1-D45D51ECBF9CQ44122680-AC21AAFE-A3D4-4177-997F-57F80C4DB7E3Q47354750-91FCC80E-A947-41A9-88B7-70C4E6DCFE55Q49044360-A853FBBA-5666-4EC9-A9B5-7EAFE90D35C0Q49164371-D3C6D822-3669-4CCF-AFBA-5E79ED15F427Q50723740-E136CC59-487C-47D8-A84A-636E8A0026C7Q50968375-4A7D88FB-127F-4DAB-BBAE-91245E69FDAEQ53430569-548506F5-F1BD-48ED-A1B6-EFE4271CBC30Q53770646-89B13751-2825-4CC5-8B5F-0B7E7206A05AQ57393673-2690EF77-4227-40E4-AF43-BE5B14EEACBFQ58726467-AE01E22C-EE81-4645-844D-A58E17469A0D
P2860
Phase transformation considerations during process development and manufacture of solid oral dosage forms
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Phase transformation considera ...... ure of solid oral dosage forms
@ast
Phase transformation considera ...... ure of solid oral dosage forms
@en
Phase transformation considera ...... ure of solid oral dosage forms
@nl
type
label
Phase transformation considera ...... ure of solid oral dosage forms
@ast
Phase transformation considera ...... ure of solid oral dosage forms
@en
Phase transformation considera ...... ure of solid oral dosage forms
@nl
prefLabel
Phase transformation considera ...... ure of solid oral dosage forms
@ast
Phase transformation considera ...... ure of solid oral dosage forms
@en
Phase transformation considera ...... ure of solid oral dosage forms
@nl
P2093
P1476
Phase transformation considera ...... ure of solid oral dosage forms
@en
P2093
Devalina Law
Eric A Schmitt
Geoff G Z Zhang
Yihong Qiu
P304
P356
10.1016/J.ADDR.2003.10.009
P407
P577
2004-02-23T00:00:00Z